#BEGIN_DRUGCARD DB06590

# AHFS_Codes:
Not Available

# ATC_Codes:
J01DI02

# Absorption:
Not Available

# Biotransformation:
Ceftaroline fosamil is converted into bioactive ceftaroline in plasma by a phosphatase enzyme. Hydrolysis of the beta-lactam ring of ceftaroline occurs to form the microbiologically inactive, open-ring metabolite ceftaroline M-1.

# Brand_Mixtures:
Not Available

# Brand_Names:
Teflaro
Zinforo

# CAS_Registry_Number:
400827-46-5

# ChEBI_ID:
70718

# Chemical_Formula:
C22H21N8O8PS4

# Chemical_IUPAC_Name:
4-(2-{[(6R,7R)-2-carboxylato-7-[(2E)-2-(ethoxyimino)-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]sulfanyl}-1,3-thiazol-4-yl)-1-methylpyridin-1-ium

# Chemical_Structure:
Not Available

# Creation_Date:
2008-03-19 10:38:49 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Ceftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria:
Acute bacterial skin and skin structure infections. 
Community-acquired bacterial pneumonia.

# Dosage_Forms:
Injection, powder, for solution	Intravenous

# Drug_Category:
Antibiotics
Cephalosporins

# Drug_Interactions:
Not Available

# Drug_Reference:
18246523	Parish D, Scheinfeld N: Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection. Curr Opin Investig Drugs. 2008 Feb;9(2):201-9.
19207097	Kanafani ZA, Corey GR: Ceftaroline: a cephalosporin with expanded Gram-positive activity. Future Microbiol. 2009 Feb;4(1):25-33. doi: 10.2217/17460913.4.1.25.
20001879	Kollef MH: New antimicrobial agents for methicillin-resistant Staphylococcus aureus. Crit Care Resusc. 2009 Dec;11(4):282-6.
20334458	Steed ME, Rybak MJ: Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens. Pharmacotherapy. 2010 Apr;30(4):375-89.
23459495	Macgowan AP, Noel AR, Tomaselli S, Bowker KE: Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother. 2013 Mar 4.

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
>100 mg/ml

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Ceftaroline fosamil

# HET_ID:
Not Available

# Half_Life:
1.60 hours (600 mg dose).

# InChI_Identifier:
InChI=1S/C22H21N8O8PS4/c1-3-38-26-13(16-25-21(43-28-16)27-39(35,36)37)17(31)24-14-18(32)30-15(20(33)34)12(9-40-19(14)30)42-22-23-11(8-41-22)10-4-6-29(2)7-5-10/h4-8,14,19H,3,9H2,1-2H3,(H4-,24,25,27,28,31,33,34,35,36,37)/b26-13+/t14-,19-/m1/s1

# InChI_Key:
InChIKey=ZCCUWMICIWSJIX-XHNDKCDBSA-N

# Indication:
Ceftaroline fosamil is indicated for the treatment of patients with the following infections caused by susceptible isolates of the designated microorganisms.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D08884

# LIMS_Drug_ID:
6591

# Mechanism_Of_Action:
Ceftaroline fosamil is an antibacterial drug.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
684.685

# Molecular_Weight_Mono:
684.01027896

# Organisms_Affected:
Gram-negative Bacteria
Gram-positive Bacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdr.net/MedMerck-full-prescribing-information/teflaro?druglabelid=158

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
The time that unbound plasma concentration of ceftaroline exceeds the minimum inhibitory concentration (MIC) of the infecting organism has been shown to best correlate with efficacy in a neutropenic murine thigh infection model with S. aureus and S. pneumoniae.

No significant effect on QTc (corrected QT interval) interval was detected at peak plasma concentration or at any other time.

# Predicted_LogP_Hydrophobicity:
-0.79

# Predicted_LogS:
-4.5

# Predicted_Water_Solubility:
2.45e-02 g/l

# Primary_Accession_No:
DB06590

# Protein_Binding:
approximately 20%.

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/teflaro-drug.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]12SCC(SC3=NC(=CS3)C3=CC=[N+](C)C=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N\OCC)\C1=NSC(NP(O)(O)=O)=N1)C([O-])=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
(6R,7R)-7-[(2Z)-2-ethoxyimino-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-3-[4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-yl]sulfanyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
Ceftaroline
PPI 0903
TAK-599
Teflaro

# Synthesis_Reference:
Not Available

# Toxicity:
LD50/LC50:
Draize test, rabbit, eye: 100 mg/24H Moderate; Oral,
mouse: LD50 = 300 mg/kg; Oral, rabbit: LD50 = 3200 mg/kg; Oral, rat:
LD50 = 980 mg/kg.

# Update_Date:
2013-04-29 14:43:38 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Ceftaroline_fosamil

# pKa_Isoelectric_Point:
Not Available

#END_DRUGCARD DB06590
